MAPPIT (MAmmalian Protein-Protein Interaction Trap) as a tool to study HIV reverse transcriptase dimerization in intact human cells

Journal of Virological Methods

Volumn 153, Issue 1, 2008, Pages 7-15

  Pattyn, Els ^a,b   Lavens, Delphine ^a,b   Van der Heyden, José ^a,b   Verhee, Annick ^a,b   Lievens, Sam ^a,b   Lemmens, Irma ^a,b   Hallenberger, Sabine ^c   Jochmans, Dirk ^c   Tavernier, Jan ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c TIBOTEC BVBA   (Belgium)

Author keywords

Efavirenz; HIV 1; MAPPIT; Protein protein interactions; Reverse transcriptase

Indexed keywords

EFAVIRENZ; PROTEIN P66; RNA DIRECTED DNA POLYMERASE;

ARTICLE; CONTROLLED STUDY; DIMERIZATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; MUTATION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; VIRUS STRAIN;

BENZOXAZINES; CELL LINE; DIMERIZATION; HIV; HIV REVERSE TRANSCRIPTASE; HUMANS; INHIBITORY CONCENTRATION 50; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN SUBUNITS; REVERSE TRANSCRIPTASE INHIBITORS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MAMMALIA;

EID: 49349104466     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2008.06.021     Document Type: Article

References (39)

1. Baillon J.G., Nashed N.T., Kumar A., Wilson S.H., and Jerina D.M. A leucine zipper-like motif may mediate HIV reverse transcriptase subunit binding. New Biol. 3 (1991) 1015-1019
2. Depollier J., Hourdou M.L., Aldrian-Herrada G., Rothwell P., Restle T., and Divita G. Insight into the mechanism of a peptide inhibitor of HIV reverse transcriptase dimerization. Biochemistry 44 (2005) 1909-1918
3. Divita G., Restle T., and Goody R.S. Characterization of the dimerization process of HIV-1 reverse transcriptase heterodimer using intrinsic protein fluorescence. FEBS Lett. 324 (1993) 153-158
4. Divita G., Restle T., Goody R.S., Chermann J.C., and Baillon J.G. Inhibition of human immunodeficiency virus type 1 reverse transcriptase dimerization using synthetic peptides derived from the connection domain. J. Biol. Chem. 269 (1994) 13080-13083
5. Divita G., Rittinger K., Geourjon C., Deleage G., and Goody R.S. Dimerization kinetics of HIV-1 and HIV-2 reverse transcriptase: a two-step process. J. Mol. Biol. 245 (1995) 508-521
6. Eyckerman S., Broekaert D., Verhee A., Vandekerckhove J., and Tavernier J. Identification of the Y985 and Y1077 motifs as SOCS3 recruitment sites in the murine leptin receptor. FEBS Lett. 486 (2000) 33-37
7. Eyckerman S., Lemmens I., Catteeuw D., Verhee A., Vandekerckhove J., Lievens S., and Tavernier J. Reverse MAPPIT: screening for protein-protein interaction modifiers in mammalian cells. Nat. Methods 2 (2005) 427-433
8. Eyckerman S., Lemmens I., Lievens S., Van der Heyden J., Verhee A., Vandekerckhove J., and Tavernier J. Design and use of a mammalian protein-protein interaction trap (MAPPIT). Sci. STKE 2002 (2002) PL18
9. Eyckerman S., Verhee A., der Heyden J.V., Lemmens I., Ostade X.V., Vandekerckhove J., and Tavernier J. Design and application of a cytokine-receptor-based interaction trap. Nat. Cell Biol. 3 (2001) 1114-1119
10. Figueiredo A., Moore K.L., Mak J., Sluis-Cremer N., de Bethune M.P., and Tachedjian G. Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol. PLoS Pathog. 2 (2006) e119
11. Ghosh M., Jacques P.S., Rodgers D.W., Ottman M., Darlix J.L., and Le Grice S.F. Alterations to the primer grip of p66 HIV-1 reverse transcriptase and their consequences for template-primer utilization. Biochemistry 35 (1996) 8553-8562
12. Grohmann D., Corradi V., Elbasyouny M., Baude A., Horenkamp F., Laufer S.D., Manetti F., Botta M., and Restle T. Small molecule inhibitors targeting HIV-1 reverse transcriptase dimerization. Chembiochem. 9 (2008) 916-922
13. Hizi A., McGill C., and Hughes S.H. Expression of soluble, enzymatically active, human immunodeficiency virus reverse transcriptase in Escherichia coli and analysis of mutants. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 1218-1222
14. Jacobo-Molina A., Ding J., Nanni R.G., Clark Jr. A.D., Lu X., Tantillo C., Williams R.L., Kamer G., Ferris A.L., Clark P., et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 6320-6324
15. Jochmans D. Novel HIV-1 reverse transcriptase inhibitors. Virus Res. 134 (2008) 171-185
16. Jochmans, D., Van Ginderen, M., Ehteshami, M., Van Schoubroeck, B., Dehertogh, P., Hallenberger, S., Götte, M., and Hertogs, K. 2007. L234F, a Unique HIV-1 RT Mutation Selected by NcRTI. Paper presented at: 14th Conference on Retroviruses and Opportunistic Infections.
17. Kohlstaedt L.A., Wang J., Friedman J.M., Rice P.A., and Steitz T.A. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256 (1992) 1783-1790
18. Lemmens I., Lievens S., Eyckerman S., and Tavernier J. Reverse MAPPIT detects disruptors of protein-protein interactions in human cells. Nat. Protoc. 1 (2006) 92-97
19. Lievens S., Lemmens I., Montoye T., Eyckerman S., and Tavernier J. Two-hybrid and its recent adaptations. Drug Discovery Today: Technol. 3 (2006) 317-324
20. Lowe D.M., Aitken A., Bradley C., Darby G.K., Larder B.A., Powell K.L., Purifoy D.J., Tisdale M., and Stammers D.K. HIV-1 reverse transcriptase: crystallization and analysis of domain structure by limited proteolysis. Biochemistry 27 (1988) 8884-8889
21. Mitsuya H., Weinhold K.J., Furman P.A., St Clair M.H., Lehrman S.N., Gallo R.C., Bolognesi D., Barry D.W., and Broder S. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. U.S.A. 82 (1985) 7096-7100
22. Montoye T., Lemmens I., Catteeuw D., Eyckerman S., and Tavernier J. A systematic scan of interactions with tyrosine motifs in the erythropoietin receptor using a mammalian 2-hybrid approach. Blood 105 (2005) 4264-4271
23. Mulky A., Sarafianos S.G., Arnold E., Wu X., and Kappes J.C. Subunit-specific analysis of the human immunodeficiency virus type 1 reverse transcriptase in vivo. J. Virol. 78 (2004) 7089-7096
24. Mulky A., Sarafianos S.G., Jia Y., Arnold E., and Kappes J.C. Identification of amino acid residues in the human immunodeficiency virus type-1 reverse transcriptase tryptophan-repeat motif that are required for subunit interaction using infectious virions. J. Mol. Biol. 349 (2005) 673-684
25. Muller B., Restle T., Weiss S., Gautel M., Sczakiel G., and Goody R.S. Co-expression of the subunits of the heterodimer of HIV-1 reverse transcriptase in Escherichia coli. J. Biol. Chem. 264 (1989) 13975-13978
26. Prasad V.R., and Goff S.P. Linker insertion mutagenesis of the human immunodeficiency virus reverse transcriptase expressed in bacteria: definition of the minimal polymerase domain. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 3104-3108
27. Restle T., Muller B., and Goody R.S. RNase H activity of HIV reverse transcriptases is confined exclusively to the dimeric forms. FEBS Lett. 300 (1992) 97-100
28. Sluis-Cremer N., Dmitrienko G.I., Balzarini J., Camarasa M.J., and Parniak M.A. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4″-amino-2″,2″-dioxo-1″,2″-oxathiole-5″,3′-[2′, 5′-bis-O-(tert-butyldimethylsilyl)-beta-d-ribofuranosyl]]]-3-ethylthy mine. Biochemistry 39 (2000) 1427-1433
29. Sluis-Cremer N., Hamamouch N., San Felix A., Velazquez S., Balzarini J., and Camarasa M.J. Structure-activity relationships of [2′,5′-bis-O-(tert-butyldimethylsilyl)-beta-d-ribofuranosyl]-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide)thymine derivatives as inhibitors of HIV-1 reverse transcriptase dimerization. J. Med. Chem. 49 (2006) 4834-4841
30. Sluis-Cremer N., and Tachedjian G. Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. Virus Res. 134 (2008) 147-156
31. Tachedjian G., Aronson H.E., de los Santos M., Seehra J., McCoy J.M., and Goff S.P. Role of residues in the tryptophan repeat motif for HIV-1 reverse transcriptase dimerization. J. Mol. Biol. 326 (2003) 381-396
32. Tachedjian G., Aronson H.E., and Goff S.P. Analysis of mutations and suppressors affecting interactions between the subunits of the HIV type 1 reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 6334-6339
33. Tachedjian G., and Goff S.P. The effect of NNRTIs on HIV reverse transcriptase dimerization. Curr. Opin. Investig. Drugs 4 (2003) 966-973
34. Tachedjian G., Moore K.L., Goff S.P., and Sluis-Cremer N. Efavirenz enhances the proteolytic processing of an HIV-1 pol polyprotein precursor and reverse transcriptase homodimer formation. FEBS Lett. 579 (2005) 379-384
35. Tachedjian G., Orlova M., Sarafianos S.G., Arnold E., and Goff S.P. Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 7188-7193
36. Tachedjian G., Radzio J., and Sluis-Cremer N. Relationship between enzyme activity and dimeric structure of recombinant HIV-1 reverse transcriptase. Proteins 60 (2005) 5-13
37. Venezia C.F., Howard K.J., Ignatov M.E., Holladay L.A., and Barkley M.D. Effects of efavirenz binding on the subunit equilibria of HIV-1 reverse transcriptase. Biochemistry 45 (2006) 2779-2789
38. Wang J., Smerdon S.J., Jager J., Kohlstaedt L.A., Rice P.A., Friedman J.M., and Steitz T.A. Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 7242-7246
39. Yu Q., Ottmann M., Pechoux C., Le Grice S., and Darlix J.L. Mutations in the primer grip of human immunodeficiency virus type 1 reverse transcriptase impair proviral DNA synthesis and virion maturation. J. Virol. 72 (1998) 7676-7680